natgillin/translations-raw huggingface dataset:
After taking the medicine it passes into the urine and attaches to the lining of the bladder, helping to form a protective layer. 
Potem ko vzamete zdravilo, to zdravilo preide v urin in se veže na sluznico mehurja ter pomaga oblikovati zaščitni sloj.
PVC/Aclar-Aluminium blister with 90 (9x10) capsules. 
Pretisni omot (PVC/Aclar/aluminij) z 90 (9 x 10) kapsulami.
In case of adverse reactions, treatment might be paused until the symptoms abate and treatment should be continued at the recommended dose after a critical balancing of the risks thereafter. 
Pri neželenih učinkih bo zdravljenje morda treba prekiniti, dokler se simptomi ne ublažijo, nato se zdravljenje nadaljuje s priporočenim odmerkom po kritičnem ovrednotenju tveganj.
In three studies, the observed difference was clearly statistically significant. 
V treh študijah je bila opažena razlika statistično značilna.
The GRA assessment was evaluated via a 7-point centred scale, in which the patients can assess their global response compared to baseline as markedly worse, moderately worse, slightly worse, no change, slightly improved, moderately improved or markedly improved. 
Globalno oceno odziva so ocenjevali s 7-stopenjsko lestvico, pri kateri lahko bolniki ocenijo svoj globalni odziv v primerjavi z izhodiščem kot občutno slabši, zmerno slabši, nekoliko slabši, brez sprememb, nekoliko izboljšan, zmerno izboljšan ali občutno izboljšan.
For early detection of retinal disorders, eye examination will be performed regularly. 
Za zgodnje odkrivanje bolezni mrežnice je treba redno izvajati preglede oči.
The hard capsules are white and non-transparent, provided in a plastic bottle with child resistant closure or plastic/aluminium blisters, packed in a carton. 
Trde kapsule so bele in neprosojne, v plastenki z za otroke varno zaporko ali v plastičnih/aluminijastih pretisnih omotih, pakiranih v škatlo.
The safety and efficacy of pentosan polysulfate sodium in children and adolescent below 18 years has not been established. 
Varnost in učinkovitost natrijevega pentozan polisulfata pri otrocih ter mladostnikih, mlajših od 18 let, nista bili dokazani.
Pharmacotherapeutic group: Urologicals, other urologicals, ATC code: G04BX15. 
Farmakoterapevtska skupina: urologiki, drugi urologiki, oznaka ATC: G04BX15
Response to treatment with pentosan polysulfate sodium should be reassessed every 6 months. 
Odziv na zdravljenje z natrijevim pentozan polisulfatom je treba ponovno oceniti vsakih 6 mesecev.
In healthy volunteers, a single parenteral administration of radioactively labelled pentosan polysulfate sodium leads to a progressive up-take of total radioactivity by the liver, spleen, and kidney (50 min after 1 mg/kg i.v. 
Pri zdravih prostovoljcih enkratni parenteralni odmerek radioaktivno označenega natrijevega pentozan polisulfata vodi do progresivnega privzema skupne radioaktivnosti v jetrih, vranici in ledvicah (50 min po 1 mg/kg i.v.
• severe mood swings or depression 
• močna nihanja razpoloženja ali depresija;
Accordingly, oral administration of pentosan polysulfate sodium 3-times daily is expected to lead to accumulation of pentosan polysulfate sodium over the first 7 days of administration (accumulation factor 5-6.7). 
V skladu s tem se pričakuje, da peroralno dajanje natrijevega pentozan polisulfata trikrat dnevno povzroči kopičenje natrijevega pentozan polisulfata v prvih 7 dneh dajanja (faktor kopičenja 5-6,7).
For storage conditions after first opening of the bottle, see section 6.3. 
Za pogoje shranjevanja po prvem odprtju plastenke glejte poglavje 6.3. pretisni omot
This leaflet was last revised in <{MM/YYYY}>. 
Navodilo je bilo nazadnje revidirano dne <{MM/YYYY}>.
Increase of ≥ 20 cc (% pts) 
Povečanje za ≥ 20 cc (% točk)
Secondary outcome measures included the O'Leary-Sant IC Symptom and Problem Index, the University of Wisconsin Symptom score, patient reported symptoms of pain/discomfort and urgency, and results of a 24-hour voiding diary. 
Ukrepi sekundarnega rezultata so vključevali indeks simptomov in problemov intersticijskega cistitisa po O'Leary-Santu, lestvico simptomov univerze v Wisconsinu, simptome bolečine/nelagodja in nujnosti, o katerih so poročali bolniki, in rezultate dnevnika 24-urnega praznjenja.
• infections, flu 
• okužbe, gripa;
A responder analysis based on a patientreported Global Response Assessment (GRA) after 24 weeks of treatment was defined as primary endpoint. 
Analiza odzivnih bolnikov na osnovi globalne ocene odziva, o katerem so poročali bolniki po 24 tednih zdravljenja, je bila opredeljena kot primarni cilj študije.
1 capsule, 3 times daily Your doctor will assess your response to elmiron every 6 months. 
Zdravnik bo ocenil vašo odzivnost na zdravilo elmiron vsakih 6 mesecev.
Total daily urine volume (cc) 
Skupna dnevna količina urina (cc)
A. MANUFACTURER RESPONSIBLE FOR BATCH RELEASE 
A. IZDELOVALEC , ODGOVOREN ZA SPROŠČANJE SERIJ
The recommended dose of pentosan polysulfate sodium is 300 mg/day taken as one 100 mg capsule orally three times daily. 
Priporočeni odmerek natrijevega pentozan polisulfata je 300 mg/dan, ki se jemlje kot ena 100miligramska kapsula peroralno trikrat dnevno.
3 voids less per day (% pts) 
3 praznjenja manj dnevno (% točk)
Comparison of those patients receiving pentosan polysulfate sodium with those not receiving pentosan polysulfate sodium (irrespective of treatment with oral hydroxyzine) revealed no statistically significant difference between the two group, but a trend for better efficacy was observed for the primary endpoint in those patients treated with pentosan polysulfate sodium (either alone or in combination with hydroxyzine) (20 of 59, 34%) compared to the those patients not receiving pentosan polysulfate sodium, but who might receive hydroxyzine (11 of 62, 18%, p0.064): 
Primerjava bolnikov, ki so prejemali natrijev pentozan polisulfat, z bolniki, ki natrijevega pentozan polisulfata niso prejemali (neodvisno od zdravljenja s peroralnim hidroksizinom), ni pokazala statistično značilne razlike med obema skupinama, vendar je bil opažen trend boljše učinkovitosti za primarni cilj študije pri bolnikih, ki so bili zdravljeni z natrijevim pentozan polisulfatom (samostojno ali v kombinaciji s hidroksizinom) (20 od 59, 34 %), v primerjavi z bolniki, ki natrijevega pentozan polisulfata niso prejemali, morda pa so prejemali hidroksizin (11 od 62, 18 %, p = 0,064):
In case no improvement is reached 6 months after treatment initiation, treatment with pentosan polysulfate sodium should be stopped. 
Če 6 mesecev po začetku zdravljenja ni napredka, je treba zdravljenje z natrijevim pentozan polisulfatom prekiniti.
Due to the weak anticoagulant effect of pentosan polysulfate sodium, elmiron must not be used in patients who actively bleed. 
Zaradi šibkega antikoagulacijskega učinka natrijevega pentozan polisulfata se zdravilo elmiron ne sme uporabljati pri bolnikih, ki aktivno krvavijo.
This binding of glycosaminoglycans to the bladder mucous reduces bacterial adherence to the inner surface of the bladder and in consequence the incidence of infections is reduced as well. 
Ta vezava glikozaminoglikanov na sluznico mehurja zmanjša priraščanje bakterij na notranjo površino mehurja, zato se zmanjša tudi pogostost okužb.
Pentosan polysulfate sodium is a weak anticoagulant. 
Natrijev pentozan polisulfat je šibek antikoagulant.
Animal studies with respect to reproductive toxicity were not conducted. 
Študij na živalih glede vpliva na sposobnost razmnoževanja niso izvedli.
What elmiron is and what it is used for elmiron is a medicine that contains the active substance pentosan polysulfate sodium. 
Kaj je zdravilo elmiron in za kaj ga uporabljamo elmiron je zdravilo, ki vsebuje učinkovino natrijev pentozan polisulfat.
• headache, back pain 
• glavobol, bolečine v hrbtu;
administration, the apparent plasma half-life after oral administration is in the range of 24-34 hours. 
dajanju hitro izloči iz obtoka, je navidezni razpolovni čas v plazmi po peroralnem dajanju v razponu 24-34 ur.
A study in healthy subjects revealed no pharmacokinetic or pharmacodynamic interactions between therapeutic doses of warfarin and pentosan polysulfate sodium. 
Študija pri zdravih osebah ni razkrila farmakokinetičnega ali farmakodinamičnega medsebojnega delovanja med terapevtskimi odmerki varfarina in natrijevega pentozan polisulfata.
Furthermore a trend for better efficacy of pentosane polysulfate sodium was observed for the patients self-assessment of an improvement of pain and urgency, despite a deviating effect observed for the evaluation of urgency via the scale. 
Poleg tega so opazili trend boljše učinkovitosti natrijevega pentozan polisulfata pri samooceni bolnikov glede izboljšanja bolečine in nujnosti kljub drugačnemu učinku, ki je bil opažen pri oceni nujnosti na lestvici.
Tell your doctor immediately if you experience visual changes such as reading difficulty and slower adjustment to low or reduced light. 
Zdravniku takoj povejte, če se pojavijo spremembe vida, kot so težave z branjem in počasno prilagajanje okolju z malo svetlobe ali zmanjšano svetlobo.
Name and address of the manufacturer responsible for batch release bene-Arzneimittel GmbH Herterichstr. 
Ime in naslov izdelovalca, odgovornega za sproščanje serij bene-Arzneimittel GmbH Herterichstr.
A trend for better efficacy under pentosan polysulfate sodium was observed for improved sexual intercourse: 
Trend boljše učinkovitosti pri uporabi natrijevega pentozan polisulfata je bil opažen pri izboljšanih spolnih odnosih:
Efficacy of treatment was evaluated based on the patient reported improvement on four typical symptoms of bladder pain syndrome: pain, urgency, frequency, and nocturia, no primary endpoint was defined. 
Učinkovitost zdravljenja so ocenjevali na podlagi poročanj bolnikov o izboljšanju štirih tipičnih simptomov sindroma bolečega mehurja, tj. bolečina, nujnost, pogostost in nokturija, medtem ko primarni cilj študije ni bil določen.
• a blood clotting disorder or increased risks of bleeding, such as using a medicine that inhibits blood clotting 
• če imate motnje strjevanja krvi ali povečano tveganje krvavitev ter jemljete zdravilo, ki zavira strjevanje krvi;
All studies describe very low systemic availability of unchanged pentosan polysulfate sodium after oral administration. 
Vse študije opisujejo zelo nizko sistemsko razpoložljivost nespremenjenega natrijevega pentozan polisulfata po peroralnem dajanju.
Capsule content Microcrystalline cellulose Magnesium stearate 
Vsebina kapsule mikrokristalna celuloza magnezijev stearat
If you forget to take elmiron 
Če ste pozabili vzeti zdravilo elmiron
Do not use this medicine after the expiry date which is stated on the label and carton after EXP. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na nalepki in škatli poleg oznake „EXP“.
In all of these studies, patients reported a better subjective improvement of bladder pain syndrome under treatment with pentosan polysulfate sodium compared to placebo. 
V vseh teh študijah so bolniki poročali o boljšem subjektivnem izboljšanju sindroma bolečega mehurja pri zdravljenju z natrijevim pentozan polisulfatom v primerjavi s placebom.
Visual symptoms might include complaints of reading difficulty and slow adjustment to low or reduced light environments. 
Vizualni simptomi lahko vključujejo težave z branjem in počasno prilagajanje okolju z malo svetlobe ali zmanjšano svetlobo.
Driving and using machines elmiron has no or negligible influence on the ability to drive and use machines. 
Vpliv na sposobnost upravljanja vozil in strojev Zdravilo elmiron nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja strojev.
About 6% of the administered dose of pentosan polysulfate sodium were excreted via urine after desulfation and depolymerisation. 
Približno 6 % uporabljenega odmerka natrijevega pentozan polisulfata se je izločilo z urinom po desulfaciji in depolimerizaciji.
• ever had a reduced number of blood platelets caused by the medicine called heparin 
• če ste kdaj imeli zmanjšano število trombocitov zaradi učinkovine heparin;
This pooled analysis showed that the percentage of patients responding to treatment with pentosan polysulfate sodium with a clinically relevant improvement in their overall assessment, pain and urgency was approximately 2-fold higher than the respective responder rates under placebo: 
Ta zbirna analiza je pokazala, da je bil delež bolnikov, ki so se odzivali na zdravljenje z natrijevim pentozan polisulfatom, s klinično značilnim izboljšanjem njihove celotne ocene, bolečine in nujnosti, približno dvakrat večji od deleža ustreznih odzivnih bolnikov pri zdravljenju s placebom:
Other medicines and elmiron 
Druga zdravila in zdravilo elmiron
Uncommon Severe Emotional Lability/Depression 
Psihiatrične motnje občasni huda čustvena labilnost/depresija
The following two studies were conducted following very comparable double-blind, randomized, placebo-controlled multicentre study designs. 
Naslednji dve študiji sta bili izvedeni po zelo primerljivih dvojno slepih, randomiziranih, s placebom kontroliranih zasnovah večcentrične študije.
Increase of ≥ 20 cc (% pts) Total daily urine volume (cc) 
Povečanje za ≥ 20 cc (% točk) Skupna dnevna količina urina (cc)
A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE 
A. IZDELOVALEC , ODGOVOREN ZA SPROŠČANJE SERIJ B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE C. DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA PROMET Z ZDRAVILOM D. POGOJI ALI OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO UPORABO
elmiron is used in adults to treat bladder pain syndrome characterised by many tiny bleeds or distinctive lesions on the bladder wall and moderate to severe pain and a frequent urge to urinate. 
Zdravilo elmiron se uporablja pri odraslih za zdravljenje sindroma bolečega mehurja, za katerega so značilne številne majhne krvavitve ali značilne lezije na steni mehurja, zmerna do močna bolečina in pogosto siljenje k uriniranju.
Pentosan polysulfate sodium has no or negligible influence on the ability to drive and use machines. 
Natrijev pentozan polisulfat nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja strojev.
Less than 10% of orally administered pentosan polysulfate sodium are slowly absorbed from the gastrointestinal tract and are available in systemic circulation in the form of unchanged pentosan polysulfate sodium or it's metabolites. 
Manj kot 10 % peroralno danega natrijevega pentozan polisulfata se počasi absorbira iz gastrointestinalnega trakta in se v sistemskem obtoku pojavlja v obliki nespremenjenega natrijevega pentozan polisulfata ali njegovih presnovkov.
Patients undergoing invasive procedures or having signs/symptoms of underlying coagulopathy or other increased risk of bleeding (due to treatment with other medicinal products influencing coagulation such as anticoagulants, heparin derivatives, thrombolytic or antiplatelet agents including acetylsalicylic acid, or nonsteroidal antiinflammatory medicinal products (see section 4.5)) should be evaluated for haemorrhagic events. 
Bolniki, pri katerih se izvajajo invazivni postopki ali ki imajo znake/simptome osnovne koagulopatije ali drugo povečano tveganje za krvavitve (zaradi zdravljenja z drugimi zdravili, ki vplivajo na koagulacijo, kot so antikoagulanti, derivati heparina, trombolitična ali protitrombocitna zdravila, vključno z acetilsalicilno kislino, ali nesteroidna protivnetna zdravila (glejte poglavje 4.5)), morajo biti ocenjeni glede možnosti pojava hemoragičnih dogodkov.
Pentosan polysulfate sodium has not been specifically studied in special patient populations like elderly or patients with renal or hepatic impairment (see section 4.4). 
Natrijev pentozan polisulfat ni bil posebno raziskan v posebnih skupinah bolnikov, kot so starejši ali bolniki z okvaro ledvic ali jeter (glejte poglavje 4.4).
In the case of an accidental overdose, patients should be evaluated for potential adverse effects of pentosan polysulfate sodium like gastrointestinal symptoms or bleeding. 
Pri nenamernem prevelikem odmerjanju je treba bolnike oceniti glede morebitnih neželenih učinkov natrijevega pentozan polisulfata, kot so gastrointestinalni simptomi ali krvavitev.
Non-clinical data reveal no special hazard for humans based on conventional repeated dose toxicity, genotoxicity and long-term carcinogenicity studies. 
Neklinični podatki na osnovi običajnih študij toksičnosti pri ponavljajočih odmerkih, genotoksičnosti in dolgoročni kancerogenosti ne kažejo posebnega tveganja za človeka.
The fourth study was following a double-blind, double-dummy, multifactorial design and evaluated the effects of pentosan polysulfate sodium and hydroxyzine in one study. 
Četrta študija je bila izvedena po dvojno slepi, dvojno zakriti, večfaktorski zasnovi in je ocenjevala učinke natrijevega pentozan polisulfata in hidroksizina v eni študiji.
A patient was counted as a responder to treatment in case a 50% improvement compared to baseline was reported for a specific symptom after 3 months of treatment. 
Bolnik je štel kot odzivni bolnik, če so po 3 mesecih zdravljenja poročali o 50-odstotnem izboljšanju za specifičen simptom v primerjavi z izhodiščem.
The second of the two very comparable studies enrolled 148 patients and demonstrated a statistically significant benefit pentosan polysulfate sodium over placebo was demonstrated on the patient reported overall improvement evaluated as primary endpoint and an the investigator-assessed overall improvement, all evaluations on pain and urgency. 
Druga od dveh zelo primerljivih študij je vključevala 148 bolnikov in pokazala statistično značilno korist natrijevega pentozan polisulfata v primerjavi s placebom, ki je bila dokazana pri oceni skupnega izboljšanja, o katerem so poročali bolniki, kot primarnem cilju študije, in pri oceni skupnega izboljšanja, o katerem so poročali preiskovalci.
An evaluation of all data generated in the study showed that for all four symptoms statistically significant more patients responded to pentosan polysulfate sodium treatment compared to placebo: 
Ocena vseh podatkov, zbranih v študiji, je pokazala, da se je pri vseh štirih simptomih statistično značilno več bolnikov odzvalo na zdravljenje z natrijevim pentozan polisulfatom v primerjavi s placebom:
Bladder pain syndrome is a diagnosis of exclusion and other urologic disorders should be eliminated by the prescriber, such as urinary tract infection or bladder cancer. 
Sindrom bolečega mehurja je diagnoza izključitve in zdravnik, ki predpisuje zdravilo, mora izključiti druge urološke motnje, kot sta okužba sečil ali rak mehurja.
The potential relatedness between these adverse events and the treatment with pentosan polysulfate sodium was not discussed in the respective publications. 
Razprave o morebitni povezanosti teh neželenih učinkov z zdravljenjem z natrijevim pentozan polisulfatom v zadevnih publikacijah ni bilo.
A pooled analysis of the data described above from placebo-controlled clinical studies was conducted to evaluate, whether patients taking oral pentosane polysulfate sodium have clear benefit from the treatment. 
Zbirna analiza zgoraj opisanih podatkov iz kliničnih študij, kontroliranih s placebom, je bila izvedena, da se oceni, ali imajo bolniki, ki peroralno jemljejo natrijev pentozan polisulfat, jasne koristi od zdravljenja.
Hepatic or renal insufficiency elmiron has not been studied in patients with hepatic or renal insufficiency. 
Zdravilo elmiron ni bilo raziskano pri bolnikih z jetrno ali ledvično insuficienco.
Therefore, pentosan polysulfate sodium should not be used during breast-feeding. 
Zato se natrijev pentozan polisulfat med dojenjem ne sme uporabljati.
Each carton contains 90 capsules. 
Ena škatla vsebuje 90 kapsul.
The adverse events reported under treatment with pentosan polysulfate sodium were comparable to those reported under treatment with placebo in regards to quality and quantity. 
Neželeni učinki, o katerih so poročali med zdravljenjem z natrijevim pentozan polisulfatom, so primerljivi s tistimi, o katerih so kvalitativno in kvantitativno poročali pri zdravljenju s placebom.
110 patients were enrolled and treated for three months in the first of the two very comparable studies. 
V prvi od dveh zelo primerljivih študij je bilo vključenih 110 bolnikov, ki so se zdravili tri mesece.
EU/1/17/1189/001 90 hard capsules EU/1/17/1189/003 300 (3 bottles x 100) hard capsules 
EU/1/17/1189/003 300°(3°plastenke°x°100) trdih kapsul
The effect of pentosan polysulfate sodium on reproductive and developmental toxicity has not been investigated. 
Učinka natrijevega pentozan polisulfata na vpliv na sposobnost razmnoževanja in razvojno toksičnost niso preučevali.
Overall, the reported systemic bioavailability after oral administration of pentosan polysulfate sodium is below 1%. 
Splošno je poročana sistemska biološka uporabnost natrijevega pentozan polisulfata po peroralnem dajanju manjša od 1 %.
Patients were randomized to four treatment group and were treated for six months with 3x100 mg pentosane polysulfate sodium, 1x50 mg hydroxyzine, both active treatments or placebo. 
Bolniki so bili randomizirani v štiri skupine zdravljenja in so bili zdravljeni šest mesecev s 3 x 100 mg natrijevega pentozan polisulfata, 1 x 50 mg hidroksizina, obema učinkovinama ali placebom.
The hypothetic mechanism of action of pentosan polysulfate sodium includes a local effect in the bladder after systemic administration and excretion into the urine by binding of glycosaminoglycans to the deficient mucous of the bladder. 
Hipotetični mehanizem delovanja natrijevega pentozan polisulfata vključuje lokalni učinek na mehur po sistemski uporabi in izločanje v urin z vezavo glikozaminoglikanov na okvarjeno sluznico mehurja.
There are no data from the use of pentosan polysulfate sodium in pregnant women. 
Podatkov o uporabi natrijevega pentozan polisulfata pri nosečnicah ni.
• breathing difficulties 
• oteženo dihanje;
The first study was a double-blind, randomized, placebo-controlled study with a planned cross-over design evaluating pentosan polysulfate sodium versus placebo. 
Prva študija je bila dvojno slepa, randomizirana, s placebom kontrolirana študija z načrtovano navzkrižno zasnovo, v kateri so ocenjevali natrijev pentozan polisulfat v primerjavi s placebom.
What elmiron looks like and contents of the pack 
Izgled zdravila elmiron in vsebina pakiranja
The most common adverse events reported from the clinical studies are headache, dizziness and gastro-intestinal events like diarrhoea, nausea, abdominal pain and rectal bleeding. 
Najpogostejši neželeni učinki, o katerih so poročali v kliničnih študijah, so glavobol, omotica in motnje prebavil in dihal, kot so driska, navzea, bolečine v trebuhu in krvavitev iz danke.
Patients with relevant hepatic or renal insufficiency should be carefully monitored when treated with pentosan polysulfate sodium. 
Bolnike s pomembno jetrno ali ledvično insuficienco je treba med zdravljenjem z natrijevim pentozan polisulfatom skrbno spremljati.
What you need to know before you take elmiron 3. 
Kaj morate vedeti, preden boste vzeli zdravilo elmiron
A statistically significant benefit of pentosan polysulfate sodium over placebo was demonstrated over the primary endpoint, the patients overall-assessment of improvement as well as on the investigators overall assessment. 
Statistično značilna korist natrijevega pentozan polisulfata v primerjavi s placebom je bila dokazana v primarnem cilju študije, pri splošni oceni izboljšanja, o kateri so poročali bolniki, ter pri splošni oceni preiskovalcev.
elmiron is not recommended during pregnancy. 
Zdravilo elmiron ni priporočljivo med nosečnostjo ali dojenjem.
The patients in both studies were treated for three months with either 3x100 mg pentosan polysulfate sodium or placebo. 
Bolniki v obeh študijah so se tri mesece zdravili s 3 x 100 mg natrijevega pentozan polisulfata ali placebom.
Furthermore volume voiding profiles over three days and the impact of treatment on pain and urgency were evaluated as secondary endpoints. 
Nadalje so kot sekundarni cilj študije ocenjevali profil volumna praznjenja v treh dneh in učinek zdravljenja na bolečino in nujnost.
• The active substance is pentosan polysulfate sodium. 
• Učinkovina je natrijev pentozan polisulfat.